Physician profile
Mark Peter Ortiz
NPI 1740796465
$9,835.50
in general payments reported to CMS, 2019-2025
51 companies · $315 in 2025
The $315 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $149 · 2021: $2,725 · 2022: $2,920 · 2023: $2,567 · 2024: $1,160 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,033 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,033.02 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,894.48 | 2021-2025 | |
| Biogen, INC. | $667.34 | 2021-2024 | Vumerity, Tysabri |
| Biohaven Pharmaceuticals, INC. | $503.89 | 2021 | |
| Ucb, INC. | $472.66 | 2021-2024 | Briviact |
| Harmony Biosciences LLC | $409.80 | 2021-2023 | Wakix |
| Genzyme Corporation | $402.59 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $389.45 | 2021-2024 | Xywav |
| Lundbeck LLC | $352.65 | 2021-2024 | Vyepti |
| Scilex Pharmaceuticals INC. | $338.43 | 2021-2024 | Ztlido |
| Biohaven Pharmaceutical Holding Company LTD. | $314.12 | 2022 | |
| Amneal Pharmaceuticals LLC | $304.86 | 2021-2024 | Rytary, Lyvispah |
| Horizon Therapeutics Plc | $233.63 | 2021-2023 | Uplizna |
| Pfizer INC. | $228.40 | 2023-2024 | |
| Lilly USA, LLC | $213.99 | 2021-2024 | Emgality, Reyvow, Amyvid |
| Amgen INC. | $207.10 | 2021-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.